Splenic marginal zone lymphoma differential diagnosis: Difference between revisions

	Splenic marginal zone lymphoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Splenic marginal zone lymphoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Staging
History and Symptoms
Physical Examination
Laboratory Findings
Biopsy
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Splenic marginal zone lymphoma differential diagnosis On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Splenic marginal zone lymphoma differential diagnosis All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Splenic marginal zone lymphoma differential diagnosis
CDC on Splenic marginal zone lymphoma differential diagnosis
Splenic marginal zone lymphoma differential diagnosis in the news
Blogs on Splenic marginal zone lymphoma differential diagnosis
Directions to Hospitals Treating Splenic marginal zone lymphoma
Risk calculators and risk factors for Splenic marginal zone lymphoma differential diagnosis

VisualWikitext

Revision as of 02:21, 2 January 2019

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]

Overview

Splenic marginal zone lymphoma must be differentiated from other diseases such as chronic lymphocytic leukemia, follicular lymphoma, and mantle cell lymphoma.^[1]

Differential Diagnosis

Splenic marginal zone lymphoma must be differentiated from other splenic B-cell lymphomas with the help of clinical, morphological, immunophenotypic and genetic data.^[2]^[3]^[4]^[5]^[6]^[7]^[8]^[9]^[10]^[11]


Differential Diagnosis	Cytogenetics	Morphology	Immunophenotype

Splenic marginal zone lymphoma	Deletion 7q, trisomy 3, trisomy 12, trisomy 18, Genes mutation NOTCH2, NFkB pathway genes (BIRC3, TNFAIP3, MAP3K14, IKBKB, MYD88 L265P)	Negative	CD20+, CD79a+IgM+ CD11c+, IgD+, DBA44+ in more than 50% of the cases CD5+, CD25+, CD103+, IgG+ in less than 50% of the cases
Splenic Diffuse red Pulp lymphoma	Uncommon: 7q deletion, trisomy 18, 17p deletion ( TP53)	Negative	CD11c+,CD20+, CD79a+ DBA44+ IgM+, IgD+, IgG+ in more than 50% of the cases CD5+, CD103+, CD123+ in less than 50% of the cases
Hairy cell leukemia variant	Common: Deletion 17p ( TP53), Uncommon: 5q gain, deletion 7q Gene mutation: MAP2K1	Positive	CD11c+, CD20+, CD79a+, CD103+, DBA44+ IgG+ in more than 50% of the cases IgD+, IgM+ in less than 50% of the cases
Hairy cell leukemia	Uncommon: 5q gain, 7q deletion gene mutation: BRAF V600E	Negative	CD11c+, CD20+, CD79a+, CD25+, CD103+, CD123+, Annexin A1+, IgM+, IgD+, IgG+ CD10+ in less than 50% of the cases
lymphoplasmacytic lymphoma	Common: 6q deletion, Uncommon: 13q deletion, 7q deletion Gene mutation: MYD88 L265P	Positive	CD11+,CD20+, CD79a+ IgM+ CD25+ in more than 50% of the cases CD5+ in less than 50% of the cases
Chronic lymphocytic leukemia	Positive	Negative	IgM+, IgD+, CD5+, CD23+, CD43+, CD79a+, LEF1+ CD20+, DBA44+ in less than 50%
Follicular lymphoma	t(14;18) translocation gene mutation: BCL2	Positive	IgM+, IgD+, CD20+, CD79a+, BCL6+ CD10+ in more than 50% CD23+ in less than 50%
Mantle cell lymphoma	t (11;14) translocation Gene mutation: CCND1	Negative	IgM+, IgD+, CD5+, CD20+, CD43+, CD79a+, BCL1+, SOX11+ BCL6+ and LEF1+ in less than 50% for the cases

References

↑ Splenic marginal zone lymphoma. Surveillance, Epidemiology, and End Results Program. http://seer.cancer.gov/seertools/hemelymph/51f6cf57e3e27c3994bd5327/. Accessed on January 14, 2016
↑ Matutes E, Oscier D, Montalban C, Berger F, Callet-Bauchu E, Dogan A, Felman P, Franco V, Iannitto E, Mollejo M, Papadaki T, Remstein ED, Salar A, Solé F, Stamatopoulos K, Thieblemont C, Traverse-Glehen A, Wotherspoon A, Coiffier B, Piris MA (March 2008). "Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria". Leukemia. 22 (3): 487–95. doi:10.1038/sj.leu.2405068. PMID 18094718.
↑ Salido M, Baró C, Oscier D, Stamatopoulos K, Dierlamm J, Matutes E, Traverse-Glehen A, Berger F, Felman P, Thieblemont C, Gesk S, Athanasiadou A, Davis Z, Gardiner A, Milla F, Ferrer A, Mollejo M, Calasanz MJ, Florensa L, Espinet B, Luño E, Wlodarska I, Verhoef G, García-Granero M, Salar A, Papadaki T, Serrano S, Piris MA, Solé F (September 2010). "Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group". Blood. 116 (9): 1479–88. doi:10.1182/blood-2010-02-267476. PMID 20479288.
↑ Kiel MJ, Velusamy T, Betz BL, Zhao L, Weigelin HG, Chiang MY, Huebner-Chan DR, Bailey NG, Yang DT, Bhagat G, Miranda RN, Bahler DW, Medeiros LJ, Lim MS, Elenitoba-Johnson KS (August 2012). "Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma". J. Exp. Med. 209 (9): 1553–65. doi:10.1084/jem.20120910. PMC 3428949. PMID 22891276.
↑ Rossi D, Trifonov V, Fangazio M, Bruscaggin A, Rasi S, Spina V, Monti S, Vaisitti T, Arruga F, Famà R, Ciardullo C, Greco M, Cresta S, Piranda D, Holmes A, Fabbri G, Messina M, Rinaldi A, Wang J, Agostinelli C, Piccaluga PP, Lucioni M, Tabbò F, Serra R, Franceschetti S, Deambrogi C, Daniele G, Gattei V, Marasca R, Facchetti F, Arcaini L, Inghirami G, Bertoni F, Pileri SA, Deaglio S, Foà R, Dalla-Favera R, Pasqualucci L, Rabadan R, Gaidano G (August 2012). "The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development". J. Exp. Med. 209 (9): 1537–51. doi:10.1084/jem.20120904. PMC 3428941. PMID 22891273.
↑ Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP, Pucciarini A, Bigerna B, Pacini R, Wells VA, Sportoletti P, Pettirossi V, Mannucci R, Elliott O, Liso A, Ambrosetti A, Pulsoni A, Forconi F, Trentin L, Semenzato G, Inghirami G, Capponi M, Di Raimondo F, Patti C, Arcaini L, Musto P, Pileri S, Haferlach C, Schnittger S, Pizzolo G, Foà R, Farinelli L, Haferlach T, Pasqualucci L, Rabadan R, Falini B (June 2011). "BRAF mutations in hairy-cell leukemia". N. Engl. J. Med. 364 (24): 2305–15. doi:10.1056/NEJMoa1014209. PMID 21663470.
↑ Waterfall JJ, Arons E, Walker RL, Pineda M, Roth L, Killian JK, Abaan OD, Davis SR, Kreitman RJ, Meltzer PS (January 2014). "High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias". Nat. Genet. 46 (1): 8–10. doi:10.1038/ng.2828. PMC 3905739. PMID 24241536.
↑ Traverse-Glehen A, Baseggio L, Bauchu EC, Morel D, Gazzo S, Ffrench M, Verney A, Rolland D, Thieblemont C, Magaud JP, Salles G, Coiffier B, Berger F, Felman P (February 2008). "Splenic red pulp lymphoma with numerous basophilic villous lymphocytes: a distinct clinicopathologic and molecular entity?". Blood. 111 (4): 2253–60. doi:10.1182/blood-2007-07-098848. PMID 18042795.
↑ Braggio E, Dogan A, Keats JJ, Chng WJ, Huang G, Matthews JM, Maurer MJ, Law ME, Bosler DS, Barrett M, Lossos IS, Witzig TE, Fonseca R (May 2012). "Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities". Mod. Pathol. 25 (5): 651–60. doi:10.1038/modpathol.2011.213. PMC 3341516. PMID 22301699.
↑ Traverse-Glehen A, Bachy E, Baseggio L, Callet-Bauchu E, Gazzo S, Verney A, Hayette S, Jallades L, Ffrench M, Salles G, Coiffier B, Felman P, Berger F (May 2013). "Immunoarchitectural patterns in splenic marginal zone lymphoma: correlations with chromosomal aberrations, IGHV mutations, and survival. A study of 76 cases". Histopathology. 62 (6): 876–93. doi:10.1111/his.12092. PMID 23611359.
↑ Xi L, Arons E, Navarro W, Calvo KR, Stetler-Stevenson M, Raffeld M, Kreitman RJ (April 2012). "Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation". Blood. 119 (14): 3330–2. doi:10.1182/blood-2011-09-379339. PMC 3321859. PMID 22210875.

Template:WH Template:WS

[cancer.gov-1] Splenic marginal zone lymphoma. Surveillance, Epidemiology, and End Results Program. http://seer.cancer.gov/seertools/hemelymph/51f6cf57e3e27c3994bd5327/. Accessed on January 14, 2016

[pmid18094718-2] Matutes E, Oscier D, Montalban C, Berger F, Callet-Bauchu E, Dogan A, Felman P, Franco V, Iannitto E, Mollejo M, Papadaki T, Remstein ED, Salar A, Solé F, Stamatopoulos K, Thieblemont C, Traverse-Glehen A, Wotherspoon A, Coiffier B, Piris MA (March 2008). "Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria". Leukemia. 22 (3): 487–95. doi:10.1038/sj.leu.2405068. PMID 18094718.

[pmid20479288-3] Salido M, Baró C, Oscier D, Stamatopoulos K, Dierlamm J, Matutes E, Traverse-Glehen A, Berger F, Felman P, Thieblemont C, Gesk S, Athanasiadou A, Davis Z, Gardiner A, Milla F, Ferrer A, Mollejo M, Calasanz MJ, Florensa L, Espinet B, Luño E, Wlodarska I, Verhoef G, García-Granero M, Salar A, Papadaki T, Serrano S, Piris MA, Solé F (September 2010). "Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group". Blood. 116 (9): 1479–88. doi:10.1182/blood-2010-02-267476. PMID 20479288.

[pmid22891276-4] Kiel MJ, Velusamy T, Betz BL, Zhao L, Weigelin HG, Chiang MY, Huebner-Chan DR, Bailey NG, Yang DT, Bhagat G, Miranda RN, Bahler DW, Medeiros LJ, Lim MS, Elenitoba-Johnson KS (August 2012). "Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma". J. Exp. Med. 209 (9): 1553–65. doi:10.1084/jem.20120910. PMC 3428949. PMID 22891276.

[pmid22891273-5] Rossi D, Trifonov V, Fangazio M, Bruscaggin A, Rasi S, Spina V, Monti S, Vaisitti T, Arruga F, Famà R, Ciardullo C, Greco M, Cresta S, Piranda D, Holmes A, Fabbri G, Messina M, Rinaldi A, Wang J, Agostinelli C, Piccaluga PP, Lucioni M, Tabbò F, Serra R, Franceschetti S, Deambrogi C, Daniele G, Gattei V, Marasca R, Facchetti F, Arcaini L, Inghirami G, Bertoni F, Pileri SA, Deaglio S, Foà R, Dalla-Favera R, Pasqualucci L, Rabadan R, Gaidano G (August 2012). "The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development". J. Exp. Med. 209 (9): 1537–51. doi:10.1084/jem.20120904. PMC 3428941. PMID 22891273.

[pmid21663470-6] Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP, Pucciarini A, Bigerna B, Pacini R, Wells VA, Sportoletti P, Pettirossi V, Mannucci R, Elliott O, Liso A, Ambrosetti A, Pulsoni A, Forconi F, Trentin L, Semenzato G, Inghirami G, Capponi M, Di Raimondo F, Patti C, Arcaini L, Musto P, Pileri S, Haferlach C, Schnittger S, Pizzolo G, Foà R, Farinelli L, Haferlach T, Pasqualucci L, Rabadan R, Falini B (June 2011). "BRAF mutations in hairy-cell leukemia". N. Engl. J. Med. 364 (24): 2305–15. doi:10.1056/NEJMoa1014209. PMID 21663470.

[pmid24241536-7] Waterfall JJ, Arons E, Walker RL, Pineda M, Roth L, Killian JK, Abaan OD, Davis SR, Kreitman RJ, Meltzer PS (January 2014). "High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias". Nat. Genet. 46 (1): 8–10. doi:10.1038/ng.2828. PMC 3905739. PMID 24241536.

[pmid18042795-8] Traverse-Glehen A, Baseggio L, Bauchu EC, Morel D, Gazzo S, Ffrench M, Verney A, Rolland D, Thieblemont C, Magaud JP, Salles G, Coiffier B, Berger F, Felman P (February 2008). "Splenic red pulp lymphoma with numerous basophilic villous lymphocytes: a distinct clinicopathologic and molecular entity?". Blood. 111 (4): 2253–60. doi:10.1182/blood-2007-07-098848. PMID 18042795.

[pmid22301699-9] Braggio E, Dogan A, Keats JJ, Chng WJ, Huang G, Matthews JM, Maurer MJ, Law ME, Bosler DS, Barrett M, Lossos IS, Witzig TE, Fonseca R (May 2012). "Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities". Mod. Pathol. 25 (5): 651–60. doi:10.1038/modpathol.2011.213. PMC 3341516. PMID 22301699.

[pmid23611359-10] Traverse-Glehen A, Bachy E, Baseggio L, Callet-Bauchu E, Gazzo S, Verney A, Hayette S, Jallades L, Ffrench M, Salles G, Coiffier B, Felman P, Berger F (May 2013). "Immunoarchitectural patterns in splenic marginal zone lymphoma: correlations with chromosomal aberrations, IGHV mutations, and survival. A study of 76 cases". Histopathology. 62 (6): 876–93. doi:10.1111/his.12092. PMID 23611359.

[pmid22210875-11] Xi L, Arons E, Navarro W, Calvo KR, Stetler-Stevenson M, Raffeld M, Kreitman RJ (April 2012). "Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation". Blood. 119 (14): 3330–2. doi:10.1182/blood-2011-09-379339. PMC 3321859. PMID 22210875.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

@@ Line 5: / Line 5: @@
 Splenic marginal zone lymphoma must be differentiated from other diseases such as  [[chronic lymphocytic leukemia]],  [[follicular lymphoma]], and [[mantle cell lymphoma]].<ref name=cancer.gov> Splenic marginal zone lymphoma. Surveillance, Epidemiology, and End Results Program. http://seer.cancer.gov/seertools/hemelymph/51f6cf57e3e27c3994bd5327/. Accessed on January 14, 2016</ref>
 ==Differential Diagnosis==
-Splenic marginal zone lymphoma must be differentiated from other diseases such as:<ref name=cancer.gov> Splenic marginal zone lymphoma. Surveillance, Epidemiology, and End Results Program. http://seer.cancer.gov/seertools/hemelymph/51f6cf57e3e27c3994bd5327/. Accessed on January 14, 2016</ref>
+Splenic marginal zone lymphoma must be differentiated from other splenic B-cell lymphomas with the help of clinical, morphological, immunophenotypic and genetic data.<ref name="pmid18094718">{{cite journal |vauthors=Matutes E, Oscier D, Montalban C, Berger F, Callet-Bauchu E, Dogan A, Felman P, Franco V, Iannitto E, Mollejo M, Papadaki T, Remstein ED, Salar A, Solé F, Stamatopoulos K, Thieblemont C, Traverse-Glehen A, Wotherspoon A, Coiffier B, Piris MA |title=Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria |journal=Leukemia |volume=22 |issue=3 |pages=487–95 |date=March 2008 |pmid=18094718 |doi=10.1038/sj.leu.2405068 |url=}}</ref><ref name="pmid20479288">{{cite journal |vauthors=Salido M, Baró C, Oscier D, Stamatopoulos K, Dierlamm J, Matutes E, Traverse-Glehen A, Berger F, Felman P, Thieblemont C, Gesk S, Athanasiadou A, Davis Z, Gardiner A, Milla F, Ferrer A, Mollejo M, Calasanz MJ, Florensa L, Espinet B, Luño E, Wlodarska I, Verhoef G, García-Granero M, Salar A, Papadaki T, Serrano S, Piris MA, Solé F |title=Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group |journal=Blood |volume=116 |issue=9 |pages=1479–88 |date=September 2010 |pmid=20479288 |doi=10.1182/blood-2010-02-267476 |url=}}</ref><ref name="pmid22891276">{{cite journal |vauthors=Kiel MJ, Velusamy T, Betz BL, Zhao L, Weigelin HG, Chiang MY, Huebner-Chan DR, Bailey NG, Yang DT, Bhagat G, Miranda RN, Bahler DW, Medeiros LJ, Lim MS, Elenitoba-Johnson KS |title=Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma |journal=J. Exp. Med. |volume=209 |issue=9 |pages=1553–65 |date=August 2012 |pmid=22891276 |pmc=3428949 |doi=10.1084/jem.20120910 |url=}}</ref><ref name="pmid22891273">{{cite journal |vauthors=Rossi D, Trifonov V, Fangazio M, Bruscaggin A, Rasi S, Spina V, Monti S, Vaisitti T, Arruga F, Famà R, Ciardullo C, Greco M, Cresta S, Piranda D, Holmes A, Fabbri G, Messina M, Rinaldi A, Wang J, Agostinelli C, Piccaluga PP, Lucioni M, Tabbò F, Serra R, Franceschetti S, Deambrogi C, Daniele G, Gattei V, Marasca R, Facchetti F, Arcaini L, Inghirami G, Bertoni F, Pileri SA, Deaglio S, Foà R, Dalla-Favera R, Pasqualucci L, Rabadan R, Gaidano G |title=The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development |journal=J. Exp. Med. |volume=209 |issue=9 |pages=1537–51 |date=August 2012 |pmid=22891273 |pmc=3428941 |doi=10.1084/jem.20120904 |url=}}</ref><ref name="pmid21663470">{{cite journal |vauthors=Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP, Pucciarini A, Bigerna B, Pacini R, Wells VA, Sportoletti P, Pettirossi V, Mannucci R, Elliott O, Liso A, Ambrosetti A, Pulsoni A, Forconi F, Trentin L, Semenzato G, Inghirami G, Capponi M, Di Raimondo F, Patti C, Arcaini L, Musto P, Pileri S, Haferlach C, Schnittger S, Pizzolo G, Foà R, Farinelli L, Haferlach T, Pasqualucci L, Rabadan R, Falini B |title=BRAF mutations in hairy-cell leukemia |journal=N. Engl. J. Med. |volume=364 |issue=24 |pages=2305–15 |date=June 2011 |pmid=21663470 |doi=10.1056/NEJMoa1014209 |url=}}</ref><ref name="pmid24241536">{{cite journal |vauthors=Waterfall JJ, Arons E, Walker RL, Pineda M, Roth L, Killian JK, Abaan OD, Davis SR, Kreitman RJ, Meltzer PS |title=High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias |journal=Nat. Genet. |volume=46 |issue=1 |pages=8–10 |date=January 2014 |pmid=24241536 |pmc=3905739 |doi=10.1038/ng.2828 |url=}}</ref><ref name="pmid18042795">{{cite journal |vauthors=Traverse-Glehen A, Baseggio L, Bauchu EC, Morel D, Gazzo S, Ffrench M, Verney A, Rolland D, Thieblemont C, Magaud JP, Salles G, Coiffier B, Berger F, Felman P |title=Splenic red pulp lymphoma with numerous basophilic villous lymphocytes: a distinct clinicopathologic and molecular entity? |journal=Blood |volume=111 |issue=4 |pages=2253–60 |date=February 2008 |pmid=18042795 |doi=10.1182/blood-2007-07-098848 |url=}}</ref><ref name="pmid22301699">{{cite journal |vauthors=Braggio E, Dogan A, Keats JJ, Chng WJ, Huang G, Matthews JM, Maurer MJ, Law ME, Bosler DS, Barrett M, Lossos IS, Witzig TE, Fonseca R |title=Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities |journal=Mod. Pathol. |volume=25 |issue=5 |pages=651–60 |date=May 2012 |pmid=22301699 |pmc=3341516 |doi=10.1038/modpathol.2011.213 |url=}}</ref><ref name="pmid23611359">{{cite journal |vauthors=Traverse-Glehen A, Bachy E, Baseggio L, Callet-Bauchu E, Gazzo S, Verney A, Hayette S, Jallades L, Ffrench M, Salles G, Coiffier B, Felman P, Berger F |title=Immunoarchitectural patterns in splenic marginal zone lymphoma: correlations with chromosomal aberrations, IGHV mutations, and survival. A study of 76 cases |journal=Histopathology |volume=62 |issue=6 |pages=876–93 |date=May 2013 |pmid=23611359 |doi=10.1111/his.12092 |url=}}</ref><ref name="pmid22210875">{{cite journal |vauthors=Xi L, Arons E, Navarro W, Calvo KR, Stetler-Stevenson M, Raffeld M, Kreitman RJ |title=Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation |journal=Blood |volume=119 |issue=14 |pages=3330–2 |date=April 2012 |pmid=22210875 |pmc=3321859 |doi=10.1182/blood-2011-09-379339 |url=}}</ref>
-* [[Chronic lymphocytic leukemia]]
-* [[Follicular lymphoma]]
-* [[Mantle cell lymphoma]]
 {| style="border: 0px; font-size: 90%; margin: 3px; width: 1000px"
 |valign=top|
@@ Line 21: / Line 18: @@
 '''Splenic marginal zone lymphoma'''
 | style="padding: 5px 5px; background: #F5F5F5;" align=center |
-'''Negative'''
+* Deletion 7q, [[trisomy]] 3, [[trisomy]] 12, [[trisomy]] 18,
+* Genes mutation [[NOTCH2]], NFkB pathway genes (BIRC3, [[TNFAIP3]], [[MAP3K14]], IKBKB, [[MYD88]] [[L265P]])
 | style="padding: 5px 5px; background: #F5F5F5;" align=center |
 '''Negative'''
 | style="padding: 5px 5px; background: #F5F5F5;" align=center|
-'''Negative'''
+* [[CD20]]+, [[CD79a]]+[[IgM]]+
+* [[CD11c]]+, [[IgD]]+, DBA44+ in more than 50% of the cases
+* [[CD5]]+, [[CD25]]+, [[CD103]]+, [[IgG]]+ in less than 50% of the cases
 |-
 | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |
-'''Chronic lymphocytic leukemia'''
+'''Splenic Diffuse red Pulp lymphoma'''
 | style="padding: 5px 5px; background: #F5F5F5;" align=center|
-'''Positive'''
+* Uncommon: 7q deletion, [[trisomy]] 18, 17p deletion ( [[TP53]])
 | style="padding: 5px 5px; background: #F5F5F5;" align=center|
 '''Negative'''
 | style="padding: 5px 5px; background: #F5F5F5;" align=center|
-'''Negative'''
+* [[CD11c]]+,[[CD20]]+, [[CD79a]]+ DBA44+
+* [[IgM]]+, [[IgD]]+, [[IgG]]+ in more than 50% of the cases
+* [[CD5]]+, [[CD103]]+, [[CD123]]+ in less than 50% of the cases
 |-
 | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |
-'''Follicular lymphoma'''
+'''Hairy cell leukemia variant'''
 | style="padding: 5px 5px; background: #F5F5F5;" align=center|
-'''Negative'''
+* Common: Deletion 17p ( [[TP53]]),
+* Uncommon: 5q gain, deletion 7q
+* Gene mutation: [[MAP2K1]]
 | style="padding: 5px 5px; background: #F5F5F5;" align=center|
 '''Positive'''
 | style="padding: 5px 5px; background: #F5F5F5;" align=center|
-'''Positive'''
+* [[CD11c]]+, [[ CD20]]+, [[CD79a]]+, [[CD103]]+, DBA44+
+* [[IgG]]+ in more than 50% of the cases
+* [[IgD]]+, [[IgM]]+ in less than 50% of the cases
 |-
 | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |
-'''Splenic Diffuse red Pulp lymphoma'''
+'''Hairy cell leukemia'''
 | style="padding: 5px 5px; background: #F5F5F5;" align=center|
-'''Positive'''
+* Uncommon: 5q gain, 7q deletion
+* gene mutation: [[BRAF V600E]]
 | style="padding: 5px 5px; background: #F5F5F5;" align=center|
 '''Negative'''
 | style="padding: 5px 5px; background: #F5F5F5;" align=center|
-'''Negative'''
+* [[CD11c]]+, [[CD20]]+, [[CD79a]]+, [[CD25]]+, [[CD103]]+, [[CD123]]+, [[Annexin A1]]+, [[IgM]]+, [[IgD]]+, [[IgG]]+
+* [[CD10]]+ in less than 50% of the cases
 |-
 | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |
-'''Hairy Celll Leukemia variant'''
+'''lymphoplasmacytic lymphoma'''
 | style="padding: 5px 5px; background: #F5F5F5;" align=center|
-'''Negative'''
+* Common: 6q deletion,
+* Uncommon: 13q deletion, 7q deletion
+* Gene mutation: [[MYD88]] L265P
 | style="padding: 5px 5px; background: #F5F5F5;" align=center|
 '''Positive'''
 | style="padding: 5px 5px; background: #F5F5F5;" align=center|
-'''Positive'''
+* [[CD11]]+,[[ CD20]]+, [[CD79a]]+ [[IgM]]+
+* [[CD25]]+ in more than 50% of the cases
+* [[CD5]]+ in less than 50% of the cases
 |-
 | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |
-'''Mantle cell lymphoma'''
+'''Chronic lymphocytic leukemia'''
 | style="padding: 5px 5px; background: #F5F5F5;" align=center|
 '''Positive'''
@@ Line 71: / Line 83: @@
 '''Negative'''
 | style="padding: 5px 5px; background: #F5F5F5;" align=center|
-''' Positive'''
+* [[IgM]]+, [[IgD]]+, [[CD5]]+, [[CD23]]+, [[CD43]]+, [[CD79a]]+, [[LEF1]]+
+* [[CD20]]+, DBA44+ in less than 50%
 |-
 | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |
-'''Hairy cell leukeia'''
+'''Follicular lymphoma'''
 | style="padding: 5px 5px; background: #F5F5F5;" align=center|
-'''Negative'''
+* t(14;18) translocation
+* gene mutation: BCL2
 | style="padding: 5px 5px; background: #F5F5F5;" align=center|
 '''Positive'''
 | style="padding: 5px 5px; background: #F5F5F5;" align=center|
-'''Positive'''
+* [[IgM]]+, [[IgD]]+, [[CD20]]+, [[CD79a]]+, [[BCL6]]+
+* [[CD10]]+ in more than 50%
+* [[CD23]]+ in less than 50%
 |-
 | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |
-'''Lymphoplasmocytic lymphoma'''
+'''Mantle cell lymphoma'''
 | style="padding: 5px 5px; background: #F5F5F5;" align=center|
-'''Positive'''
+* t (11;14) translocation
+* Gene mutation: CCND1
 | style="padding: 5px 5px; background: #F5F5F5;" align=center|
 '''Negative'''
 | style="padding: 5px 5px; background: #F5F5F5;" align=center|
-''' Positive'''
+* [[IgM]]+, [[IgD]]+, [[CD5]]+, [[CD20]]+, [[CD43]]+, [[CD79a]]+, [[BCL1]]+, [[SOX11]]+
+* [[BCL6]]+ and [[LEF1]]+ in less than 50% for the cases
 |}

Splenic marginal zone lymphoma differential diagnosis: Difference between revisions

Revision as of 02:21, 2 January 2019

Overview

Differential Diagnosis

References

Navigation menu